Compare LWLG & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | MRVI |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.6M | 472.8M |
| IPO Year | 2011 | 2020 |
| Metric | LWLG | MRVI |
|---|---|---|
| Price | $8.14 | $2.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | ★ 6.1M | 1.9M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.79 | 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | $236,855.00 | ★ $185,743,000.00 |
| Revenue This Year | N/A | $12.44 |
| Revenue Next Year | N/A | $7.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $0.83 | $1.67 |
| 52 Week High | $9.03 | $4.11 |
| Indicator | LWLG | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 63.41 | 37.81 |
| Support Level | $3.46 | $2.57 |
| Resistance Level | $8.42 | $2.88 |
| Average True Range (ATR) | 0.91 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 70.86 | 18.75 |
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.